Decode Genetics named Linda Buck to its board of directors, the Reykjavik-Icleand based company said yesterday.
Buck received a Nobel Prize in physiology or medicine in 2004 for her discoveries on the workings of the olfactory system. She is the Associate Director of the Basic Sciences Division at Fred Hutchinson Cancer Research Center in Seattle, WA, and a Howard Hughes Medical Institute investigator. She also is an affiliate professor of physiology and biophysics at the University of Washington.
Prior to her current positions, Dr. Buck was a professor of neurobiology at Harvard Medical School and received her PhD in immunology from the University of Texas Southwestern Medical Center at Dallas.
Lentigen, a privately held biotechnology company founded less than a year ago, appointed a team of executives to lead its manufacturing, business development, operations, research and development divisions, the company said last week.
Lentigen founder Boro Dropulic is the company's CEO. Prior to Lentigen, Dropulic founded and was chief scientific officer of VIRxSYS. A Fogarty Fellow at the National Institutes of Health, he obtained his Ph.D. from the University of Western Australia.
Yung Nien Chang joined Lentigen as vice-president of vector development. Previously he was vice-president of R&D at VIRxSYS. He was also senior scientist and group leader at Genetic Therapy, which later merged with Novartis.
Lentigen's vice-president of business development, Gregory J. Feulner, previously held posts as vice-president of business development for Galileo Genomics and director of business development and transactions at Gene Logic. He received his Ph.D. biochemistry from Pennsylvania State University and completed postdoctoral fellowships from the National Institutes of Health and the Johns Hopkins School of Medicine.
John Woolford joined Lentigen as director of business planning. He was most recently vice-president and equity analyst at Legg Mason Wood Walker. He also held positions in the contract manufacturing division of MedImmune and Primedica, now a subsidiary of Charles River Laboratories.
Ivan Labat has joined the restructuring team at Genesis Bioventures to provide advanced bioinformatics analysis capabilities to Genesis and its breast cancer diagnostic portfolio company, Biomedical Diagnostics.
Experigen, a management company retained by Genesis, made the announcement last week.
A co-inventor on 42 patents, Labat received his doctorate degrees in molecular biology and physiology from the University of Belgrade. He was the scientific founder of Hyseq, now known as Nuvelo.